GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Debt-to-Asset

Oncolytics Biotech (Oncolytics Biotech) Debt-to-Asset : 0.01 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Debt-to-Asset?

Oncolytics Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. Oncolytics Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. Oncolytics Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $28.94 Mil. Oncolytics Biotech's debt to asset for the quarter that ended in Dec. 2023 was 0.01.


Oncolytics Biotech Debt-to-Asset Historical Data

The historical data trend for Oncolytics Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Debt-to-Asset Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.01 0.01 0.01 0.01

Oncolytics Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.02 0.01 0.01

Competitive Comparison of Oncolytics Biotech's Debt-to-Asset

For the Biotechnology subindustry, Oncolytics Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Debt-to-Asset falls into.



Oncolytics Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Oncolytics Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Oncolytics Biotech's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncolytics Biotech  (NAS:ONCY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Oncolytics Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.